VP
venBio Partners Portfolio holdings
AUM
$115M
This Quarter Return
-1.43%
1 Year Return
-33.99%
3 Year Return
+221.07%
5 Year Return
+224.54%
10 Year Return
–
AUM
$115M
AUM Growth
+$115M
(-7.1%)
Cap. Flow
-$62.6M
Cap. Flow
% of AUM
-54.53%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
7
New
–
Increased
1
Reduced
2
Closed
1
Top Buys
| 1 |
ALMS
Alumis Inc. Common Stock
ALMS
|
$5.5M |
Top Sells
| 1 |
Lyell Immunopharma
LYEL
|
$58.6M |
| 2 |
SLRN
ACELYRIN
SLRN
|
$9.4M |
| 3 |
ARTV
Artiva Biotherapeutics, Inc. Common Stock
ARTV
|
$75.5K |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Pharvaris
PHVS
$1.39B
| $75.5M | 65.78% | 4,289,304 | – | – |
|
2
Harmony Biosciences
HRMY
$2.12B
| $15.5M | 13.47% | 489,194 | – | – |
|
|
ALMS
3
Alumis Inc. Common Stock
ALMS
$479M
| $13.9M | 12.08% | 4,619,803 +1,832,405 | +66% | +$5.5M |
|
|
4
Lyell Immunopharma
LYEL
$213M
| $4.19M | 3.65% | 473,479 -6,628,711 | -93% | -$58.6M |
|
5
ALX Oncology
ALXO
$62.7M
| $4.03M | 3.51% | 9,699,925 | – | – |
|
|
ARTV
6
Artiva Biotherapeutics, Inc. Common Stock
ARTV
$76.7M
| $1.73M | 1.51% | 1,148,975 -50,000 | -4% | -$75.5K |
|
|
SLRN
7
DELISTED
ACELYRIN
SLRN
| – | – | -3,806,410 | Closed | -$9.4M |
|